Researchers in New Zealand and Australia published a systematic review and meta-analysis on Wednesday in Seminars in Arthritis and Rheumatism that found a lower one-year death rate with rituximab than with cyclophosphamide among people with ANCA-associated vasculitis.
The analysis pooled 48 studies covering 5,050 adults starting induction therapy. The estimated one-year mortality was 10.7% with cyclophosphamide and 5.9% with rituximab, a statistically significant difference favoring the B-cell–depleting drug, ANCA Vasculitis News reported.
“Whilst the choice of induction therapy in AAV is known to contribute to risk of disease relapse, the impact of induction therapy on mortality rate in AAV is less clear,” the authors wrote. “The difference in mortality between induction therapy with cyclophosphamide and rituximab has not been determined.”
The survival signal was strongest in studies where most participants had granulomatosis with polyangiitis, the most common form of AAV, and in cohorts with lower disease activity at diagnosis. In the five randomized trials that directly compared the two agents, cyclophosphamide showed a small, non-significant survival edge.
Rituximab, marketed as Rituxan in the United States and MabThera in Europe, targets CD20-positive B cells. Cyclophosphamide, the older standard, carries well-documented risks of infertility, infection, and malignancy. The review included 15 randomized controlled trials, five prospective studies, and 28 retrospective analyses. Patients receiving rituximab tended to be older and more likely to be women, a selection bias the authors flagged as a key limitation.
| Induction agent | Patients | Pooled 12-month mortality |
|---|---|---|
| Cyclophosphamide | 3,553 | 10.7% |
| Rituximab | 1,183 | 5.9% |
About one-third of participants had GPA, roughly one-quarter had microscopic polyangiitis, and 3% had eosinophilic granulomatosis with polyangiitis, based on available data. Most patients in the included studies also received glucocorticoids during induction.
The researchers acknowledged that the retrospective design of most included studies makes the findings vulnerable to confounding by indication. They called for further randomized trial data to directly compare the two drugs for induction treatment of AAV, specifically for the remission of GPA. Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality